Barbara H. Stokes

Barbara H. Stokes

Auto-generated profile, based on publicly available information

Barbara H. Stokes

Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AUAline Uwimana
Aline Uwimana
ELEric Legrand
Eric Legrand
BSBarbara H. Stokes
Barbara H. Stokes
JNJean-Louis Mangala Ndikumana
Jean-Louis Mangala Ndikumana
MWMarian Warsame
Marian Warsame
Didier MenardDidier Menard
Didier Menard
Artemisinin resistance (delayed P. falciparum clearance following artemisinin-based combination therapy), is widespread across Southeast Asia but to date has not been reported in Africa1–4. Here we genotyped the P. falciparum K13 (Pfkelch13) propeller domain, mutations in which can mediate artemisinin resistance5,6, in pretreatment samples collected from recent dihydroarteminisin-piperaquine and artemether-lumefantrine efficacy trials in Rwanda7. While cure rates were >95% in both treatment arms, the Pfkelch13 R561H mutation was identified in 19 of 257 (7.4%) patients at Masaka. Phylogenetic analysis revealed the expansion of an indigenous R561H lineage. Gene editing confirmed that this mutation can drive artemisinin resistance in vitro. This study provides evidence for the de novo emergence of Pfkelch13-mediated artemisinin resistance in Rwanda, potentially compromising the continued success of antimalarial chemotherapy in Africa.

19 July 2021 in eLife
Verified
Journal Article
Open access
BSBarbara H Stokes
Barbara H Stokes
SDSatish K Dhingra
Satish K Dhingra
KRKelly Rubiano
Kelly Rubiano
SMSachel Mok
Sachel Mok
JSJudith Straimer
Judith Straimer
DFDavid A Fidock
David A Fidock
The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failures across Southeast Asia. In Africa, K13-propeller genotyping confirms the emergence of the R561H mutation in Rwanda and highlights the continuing dominance of wild-type K13 elsewhere. Using gene editing, we show that R561H, along with C580Y and M579I, confer elevated in vitro ART resistance in some African strains, contrasting with minimal changes in ART susceptibility in others. C580Y and M579I cause substantial fitness costs, which may slow their dissemination in high-transmission settings, in contrast with R561H that in African 3D7 parasites is fitness neutral. In Cambodia, K13 genotyping highlights the increasing spatio-temporal dominance of C580Y. Editing multiple K13 mutations into a panel of Southeast Asian strains reveals that only the R561H variant yields ART resistance comparable to C580Y. In Asian Dd2 parasites C580Y shows no fitness cost, in contrast with most other K13 mutations tested, including R561H. Editing of point mutations in ferredoxin or mdr2, earlier associated with resistance, has no impact on ART susceptibility or parasite fitness. These data underline the complex interplay between K13 mutations, parasite survival, growth and genetic background in contributing to the spread of ART resistance.

22 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSachel Mok
Sachel Mok
BSBarbara H. Stokes
Barbara H. Stokes
NGNina F. Gnädig
Nina F. Gnädig
LRLeila S. Ross
Leila S. Ross
TYTomas Yeo
Tomas Yeo
DFDavid A. Fidock
David A. Fidock
The emergence and spread of artemisinin resistance, driven by mutations in Plasmodium falciparum K13, has compromised antimalarial efficacy and threatens the global malaria elimination campaign. By applying systems-based quantitative transcriptomics, proteomics, and metabolomics to a panel of isogenic K13 mutant or wild-type P. falciparum lines, we provide evidence that K13 mutations alter multiple aspects of the parasite’s intra-erythrocytic developmental program. These changes impact cell-cycle periodicity, the unfolded protein response, protein degradation, vesicular trafficking, and mitochondrial metabolism. K13-mediated artemisinin resistance in the Cambodian Cam3.II line was reversed by atovaquone, a mitochondrial electron transport chain inhibitor. These results suggest that mitochondrial processes including damage sensing and anti-oxidant properties might augment the ability of mutant K13 to protect P. falciparum against artemisinin action by helping these parasites undergo temporary quiescence and accelerated growth recovery post drug elimination.

30 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DQDeyun Qiu
Deyun Qiu
JPJinxin V. Pei
Jinxin V. Pei
JRJames E. O. Rosling
James E. O. Rosling
VTVandana Thathy
Vandana Thathy
DLDongdi Li
Dongdi Li
ALAdele M. Lehane
Adele M. Lehane
Diverse compounds target thePlasmodium falciparumNa+pump PfATP4, with cipargamin and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin, recrudescent parasites emerged, with most having a G358S mutation in PfATP4. Here, we show that PfATP4G358Sparasites can withstand micromolar concentrations of cipargamin and (+)-SJ733, while remaining susceptible to antimalarials that do not target PfATP4. The G358S mutation in PfATP4, and the equivalent mutation inToxoplasma gondiiATP4, decrease the sensitivity of ATP4 to inhibition by cipargamin and (+)-SJ733, thereby protecting parasites from disruption of Na+regulation. The G358S mutation reduces the affinity of PfATP4 for Na+and is associated with an increase in the parasite’s resting cytosolic [Na+]. However, no defect in parasite growth or transmissibility is observed. Our findings suggest that PfATP4 inhibitors in clinical development should be tested against PfATP4G358Sparasites, and that their combination with unrelated antimalarials may mitigate against resistance development.

22 December 2020 in mBio
Verified
Journal Article
Open access
PDF file
NSNelson Simwela
Nelson Simwela
BSBarbara Stokes
Barbara Stokes
DADana Aghabi
Dana Aghabi
MBMatt Bogyo
Matt Bogyo
DFDavid Fidock
David Fidock
AWAndrew Waters
Andrew Waters
Recent successes in malaria control have been seriously threatened by the emergence of Plasmodium falciparum parasite resistance to the frontline artemisinin drugs in Southeast Asia. P. falciparum artemisinin resistance is associated with mutations in the parasite K13 protein, which associates with a delay in the time required to clear the parasites upon drug treatment. Gene editing technologies have been used to validate the role of several candidate K13 mutations in mediating P. falciparum artemisinin resistance in vitro under laboratory conditions. Nonetheless, the causal role of these mutations under in vivo conditions has been a matter of debate. Here, we have used CRISPR/Cas9 gene editing to introduce K13 mutations associated with artemisinin resistance into the related rodent-infecting parasite, Plasmodium berghei . Phenotyping of these P. berghei K13 mutant parasites provides evidence of their role in mediating artemisinin resistance in vivo , which supports in vitro artemisinin resistance observations. However, we were unable to introduce some of the P. falciparum K13 mutations (C580Y and I543T) into the corresponding amino acid residues, while other introduced mutations (M476I and R539T equivalents) carried pronounced fitness costs. Our study provides evidence of a clear causal role of K13 mutations in modulating susceptibility to artemisinins in vitro and in vivo using the well-characterized P. berghei model. We also show that inhibition of the P. berghei proteasome offsets parasite resistance to artemisinins in these mutant lines.

27 May 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AUAline Uwimana
Aline Uwimana
ELEric Legrand
Eric Legrand
BSBarbara H. Stokes
Barbara H. Stokes
JNJean-Louis Mangala Ndikumana
Jean-Louis Mangala Ndikumana
MWMarian Warsame
Marian Warsame
Didier MenardDidier Menard
Didier Menard